1. Home
  2. ALLO vs KRNY Comparison

ALLO vs KRNY Comparison

Compare ALLO & KRNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • KRNY
  • Stock Information
  • Founded
  • ALLO 2017
  • KRNY 1884
  • Country
  • ALLO United States
  • KRNY United States
  • Employees
  • ALLO N/A
  • KRNY N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • KRNY Savings Institutions
  • Sector
  • ALLO Health Care
  • KRNY Finance
  • Exchange
  • ALLO Nasdaq
  • KRNY Nasdaq
  • Market Cap
  • ALLO 371.8M
  • KRNY 410.4M
  • IPO Year
  • ALLO 2018
  • KRNY 2005
  • Fundamental
  • Price
  • ALLO $1.11
  • KRNY $6.16
  • Analyst Decision
  • ALLO Strong Buy
  • KRNY Buy
  • Analyst Count
  • ALLO 10
  • KRNY 2
  • Target Price
  • ALLO $8.90
  • KRNY $7.75
  • AVG Volume (30 Days)
  • ALLO 4.1M
  • KRNY 275.4K
  • Earning Date
  • ALLO 05-13-2025
  • KRNY 04-24-2025
  • Dividend Yield
  • ALLO N/A
  • KRNY 7.07%
  • EPS Growth
  • ALLO N/A
  • KRNY N/A
  • EPS
  • ALLO N/A
  • KRNY N/A
  • Revenue
  • ALLO N/A
  • KRNY $148,135,000.00
  • Revenue This Year
  • ALLO N/A
  • KRNY $2.69
  • Revenue Next Year
  • ALLO $9.07
  • KRNY $24.18
  • P/E Ratio
  • ALLO N/A
  • KRNY N/A
  • Revenue Growth
  • ALLO N/A
  • KRNY 3.61
  • 52 Week Low
  • ALLO $0.86
  • KRNY $5.31
  • 52 Week High
  • ALLO $3.78
  • KRNY $8.59
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 38.30
  • KRNY 43.59
  • Support Level
  • ALLO $1.07
  • KRNY $6.20
  • Resistance Level
  • ALLO $1.15
  • KRNY $6.34
  • Average True Range (ATR)
  • ALLO 0.14
  • KRNY 0.15
  • MACD
  • ALLO -0.01
  • KRNY -0.02
  • Stochastic Oscillator
  • ALLO 27.17
  • KRNY 14.96

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About KRNY Kearny Financial Corp

Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. It is also heavily into secured and unsecured business and consumer loans. The bank's primary source of income is net interest income.

Share on Social Networks: